Breast Implant PMA Timeframes Tested By Inamed “Not-Approvable” Letter
This article was originally published in The Gray Sheet
Executive Summary
Firms seeking premarket approval for silicone breast implants should conduct tests designed to more closely predict rupture and gel bleed under real-world conditions, according to new FDA draft guidelines
You may also be interested in...
Inamed To Carry On Quest For Silicone Implant Approval After Panel Rejection
Inamed's 20% rupture rate for reconstruction breast implants would drop with the removal of the Style 153 double-lumen implants, according to members of FDA's General & Plastic Surgery Devices Panel
Inamed To Carry On Quest For Silicone Implant Approval After Panel Rejection
Inamed's 20% rupture rate for reconstruction breast implants would drop with the removal of the Style 153 double-lumen implants, according to members of FDA's General & Plastic Surgery Devices Panel
Rejected Device Applicants Conserve R&D Resources, Sidestep Confrontation
Implantable device manufacturers who encountered FDA resistance in 2004 after favorable panel reviews are applying novel premarket data collection techniques to avoid conducting further clinical trials